These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 9433512

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism: A Tissue Doppler Study.
    Cesari M, Letizia C, Angeli P, Sciomer S, Rosi S, Rossi GP.
    Circ Cardiovasc Imaging; 2016 Jun; 9(6):. PubMed ID: 27307552
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism.
    Indra T, Holaj R, Štrauch B, Rosa J, Petrák O, Šomlóová Z, Widimský J.
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1109-17. PubMed ID: 25271250
    [Abstract] [Full Text] [Related]

  • 29. Left ventricular hypertrophy in ADPKD: changing demographics.
    Alam A, Perrone RD.
    Curr Hypertens Rev; 2013 Feb; 9(1):27-31. PubMed ID: 23971641
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A primary aldosteronism-like phenotype identified with the aldosterone-to-angiotensin II ratio in black men: the SABPA study.
    van Rooyen JM, Poglitsch M, Huisman HW, Gafane-Matemane LF, Breet Y, Malan L.
    Cardiovasc J Afr; 2013 Feb; 31(3):130-135. PubMed ID: 31781716
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.
    Weber KT, Brilla CG.
    Circulation; 1991 Jun; 83(6):1849-65. PubMed ID: 1828192
    [Abstract] [Full Text] [Related]

  • 38. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V, Devereux RB.
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [Abstract] [Full Text] [Related]

  • 39. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism.
    Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M.
    Hypertension; 1991 Jun; 17(6 Pt 2):1057-62. PubMed ID: 1828457
    [Abstract] [Full Text] [Related]

  • 40. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma.
    Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF.
    Am J Hypertens; 1993 Nov; 6(11 Pt 1):907-13. PubMed ID: 8305163
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.